Literature DB >> 29714095

Impact of Obesity on Fosphenytoin Volume of Distribution in Pediatric Patients.

Ashley B Prusakov1, Anup D Patel1, Justin W Cole1,2.   

Abstract

The impact of body habitus on fosphenytoin pharmacokinetics is poorly understood in pediatric patients. This retrospective, single-center review examined differences in fosphenytoin volume of distribution (VD) between children with normal and obese body habitus. From 2013 to 2015, patients 2 to 18 years of age who received a loading dose of fosphenytoin were identified. Thirty-seven patients met inclusion criteria. Mean total serum phenytoin concentration was 25.3 ± 6.5 μg/mL in the nonobese group and 29.5 ± 7.6 μg/mL in the obese group ( P = .09). VD was not significantly different between obese and nonobese groups, 0.92 ± 0.26 L/kg and 0.97 ± 0.48 L/kg ( P = .76), respectively. In contrast to adult studies, these data suggest that fosphenytoin dose adjustments for obese children may be unnecessary.

Entities:  

Keywords:  antiepileptic drugs; children; pediatric; status epilepticus; treatment

Mesh:

Substances:

Year:  2018        PMID: 29714095     DOI: 10.1177/0883073818770801

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  1 in total

1.  Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus.

Authors:  Abhishek G Sathe; Usha Mishra; Vijay Ivaturi; Richard C Brundage; James C Cloyd; Jordan J Elm; James M Chamberlain; Robert Silbergleit; Jaideep Kapur; Daniel H Lowenstein; Shlomo Shinnar; Hannah R Cock; Nathan B Fountain; Lynn Babcock; Lisa D Coles
Journal:  J Clin Pharmacol       Date:  2021-01-12       Impact factor: 2.860

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.